GlassScriptPhysician profile
Mubarak Sayyar
NPI 1699038653
$13,862.70
in general payments reported to CMS, 2019-2025
19 companies · $5,363 in 2025
The $5,363 reported for 2025 was more than what 91% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $208 · 2020: $26.27 · 2021: $220 · 2022: $345 · 2023: $235 · 2024: $7,466 · 2025: $5,363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $10K · Food and Beverage: $2,941.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $10,122.47 |
| Food and Beverage | $2,941.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $7,448.18 | 2019-2025 | Overstitch Endoscopic Suturing System, Axios, Exalt Model D |
| Olympus Corporation of The Americas | $5,108.33 | 2024-2025 | Disposable Distal Attachment, Single Use Electrosurgical Knife Kd-655, Olympus |
| Abbvie INC. | $242.12 | 2022-2025 | Rinvoq, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $232.10 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $195.47 | 2022-2023 | Gattex |
| Stryker Corporation | $118.96 | 2024 | Stryker |
| Ardelyx, INC. | $99.41 | 2023 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $85.80 | 2019 | |
| Janssen Biotech, INC. | $74.83 | 2024-2025 | Stelara, Tremfya |
| Mallinckrodt Hospital Products INC. | $62.33 | 2022-2024 | Terlivaz |
| Merit Medical Systems INC | $31.77 | 2025 | Endomaxx Stent and Delivery System, Elation Balloon Dilator |
| Gilead Sciences, INC. | $28.91 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.37 | 2023 | Cyltezo |
| E.R. Squibb & Sons, L.L.C. | $24.83 | 2024 | Zeposia |
| Merck Sharp & Dohme LLC | $20.25 | 2024 | Gardasil 9, Capvaxive, Gardasil |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $18.94 | 2024 | Voquezna |
| Pfizer INC. | $16.83 | 2024 | |
| Redhill Biopharma INC. | $13.62 | 2020 | |
| Dynavax Technologies Corporation | $12.65 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mubarak Sayyar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.